Report: First Vaccines, then Antivirals. Will the Anti-Inflammatory Be the Next Success Story in...
New Report on Revive Therapeutics (RVVTF, RVV). Ushering in Advances in Anti-Inflammatory and Antioxidant Drugs, as a Tool Against Covid.
Early Bird Gets the Worm?
Here's...
Our Best Risk to Reward Idea Ever?
Adding Revive Therapeutics (RVVTF, RVV.CN) to the "2022, Biotech 12 Pack, 12 Biotech Stocks We Expect to Double" Watch List*.
If not our best ever,...
Revive Therapeutics Updates, on Phase III Clinical Trial!
Michael Frank, CEO of the Company commented, "We are now in the final stages in our Phase 3 study.."
Revive Therapeutics Provides Update on...
Revive Therapeutics (RVVTF) Provides Update of Psilocybin Pharmaceutical Programs
IRB approval to initiate Phase 2 study for methamphetamine abuse disordersAdvancing psilocybin oral thin film, microneedle patch and biosynthesis programs
TORONTO, Jan. 17, 2022 (GLOBE...
Tax Loss Selling Bargain? Adding Aditxt (ADTX).
Adding Aditxt (ADTX) to the upcoming "2022 Biotech 6-Pack, Stocks We Expect to Double" Watch List.
We're sitting in a hotel room in Chicago minding...
Dalrada (DFCO). Our 11th and Latest Ten Bagger.
We've actually had many more than 11 ten-baggers, as we report on companies which aren't clients. This is our 11th client we should say,...
The Race to Develop Therapeutics for COVID. The Small Caps Fight for a Treatment...
The Second Wave: Biopharma Players Race to Develop Therapeutics for COVID-19 (BioSPace) December 21.
Revive Therapeutics (RVTTF), RedHill BioPharma (RDHL), AI Pharma (Private), Apilli Thera...
Ehave (EHVVF) Announces Update On Ehave Medical App With The Launch Of Covid Vaccine...
Ehave's Covid Passport provides small businesses a tool to verify Covid-19 vaccination, and a suite of products to improve both the mental and overall...
Telehealth: Contactless Health Screening from Ehave (EHVVF) and VastMinz.
Contactless Health Screening
Ehave acquires License covering G-20 Countries for all Psychedelic use, AI-Powered Telehealth Technology To Capture Physiological Vitals From Vastmindz; Prepares To Run...
Dyadic (DYAI) Scores $10M deal with Sorrento Therapeutics (SNRE).
Share Price up 27% ($4.63 up $1.04) as Wall Street Sorts out the Terms of the Deal.
We've had a Long History With Dyadic Dating...
Latest article
Jeffrey Gundlach: Reckoning is Coming.
Jeffrey Edward Gundlach is a businessman, fund manager, and philanthropist. He is the founder of DoubleLine Capital, an investment firm.
On 11 November 2020, Gundlach remarked in an interview with...
Who’s the Next Eric Sprott?
Eric Sprott, on Who is the Next Eric Sprott!
To say Eric Sprott has left a legendary mark on the world of mining investment would...
Perpetua (PPTA) Raises $300 Million.
Not a bad day in Idaho. $300 million banked! We look at the dip as a buying opportunity, as does John Paulson & Co.,...
